Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28525698 | 0.91 | CFTR (0.38) | ATMNPC1CASP3RAB9ASMN1; SMN2 | |
| SCHEMBL20951861 | 0.86 | NNMT (0.44) | ATMNPC1CASP3RAB9ASMN1; SMN2 | |
| SCHEMBL9641326 | 0.81 | ATM (0.42) | ATMTSHRKDM4EL3MBTL1MAPT | |
| SCHEMBL17490653 | 0.81 | KDM4E (0.44) | ATMTSHRKDM4EL3MBTL1MAPT | |
| SCHEMBL17558778 | 0.81 | SOS1 (0.43) | TSHRKDM4EL3MBTL1MAPK1ALDH1A1 | |
| SCHEMBL29574200 | 0.81 | SOS1 (0.43) | TSHRKDM4EL3MBTL1MAPK1ALDH1A1 | |
| SCHEMBL21232045 | 0.81 | KDM4E (0.51) | ATMTSHRKDM4EMAPTALDH1A1 | |
| SCHEMBL30955590 | 0.80 | MAPT (0.40) | ATMTSHRKDM4EL3MBTL1MAPT | |
| SCHEMBL21722820 | 0.80 | MAPT (0.40) | ATMTSHRKDM4EL3MBTL1MAPT | |
| SCHEMBL9318646 | 0.80 | MAPK1 (0.49) | ATMTSHRKDM4EL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-13 | — | — | US | disclosed |
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (US) | 2022-11-03 | — | — | US | disclosed |
| US-11466017-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3463343-B1 | HETEROCYCLIC INHIBITORS OF PTPN11 | UNIV TEXAS (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | Cantero Therapeutics, Inc. | 2021-10-14 | — | — | US | disclosed |
| CN-109475531-B | Heterocyclic inhibitors of PTPN11 | 得克萨斯州立大学董事会 | 2021-08-17 | — | — | CN | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| EP-3814326-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-05-05 | — | — | EP | disclosed |
| US-20210017182-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-01-21 | — | — | US | disclosed |
| US-10851110-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-02-13 | — | — | US | disclosed |
| CN-110225911-A | Oxadiazolone transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2019-09-10 | — | — | CN | disclosed |
| US-20190270746-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-09-05 | — | — | US | disclosed |
| US-10280171-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3463343-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | Board of Regents, University of Texas System (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-109475531-A | The heterocycle inhibitor of PTPN11 | 得克萨斯州立大学董事会 | 2019-03-15 | — | — | CN | disclosed |
| WO-2017210134-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | ATM 827/4885NPC1 3222/4885CASP3 3451/4885 |
| US-11466017-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | ATM 827/4885NPC1 3222/4885CASP3 3451/4885 |
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | ATM 3420/4885NPC1 1218/4885CASP3 2446/4885 |
| US-20210017182-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | ATM 827/4885NPC1 3222/4885CASP3 3451/4885 |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | ATM 827/4885NPC1 3222/4885CASP3 3451/4885 |
| US-10851110-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | ATM 827/4885NPC1 3222/4885CASP3 3451/4885 |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | DPYD, TYMP, HAVCR2 | ATM 2959/4885NPC1 830/4885CASP3 2650/4885 |
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | ATM 925/4885NPC1 3099/4885CASP3 3433/4885 |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | ATM 3420/4885NPC1 1218/4885CASP3 2446/4885 |
| US-20190270746-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | ATM 827/4885NPC1 3222/4885CASP3 3451/4885 |
| US-10280171-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | ATM 827/4885NPC1 3222/4885CASP3 3451/4885 |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | PTPN11, PTPRJ, PTPRCAP | ATM 925/4885NPC1 3099/4885CASP3 3433/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | ATM 827/4885NPC1 3222/4885CASP3 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.